Search results
Showing 511 to 525 of 676 results for diabetes
person's risk of complications (possibly because of comorbidities, such as diabetes or immunosuppression) and any previous antibiotic...
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for newly diagnosed and pre-existing chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
PICO negative pressure wound dressings for closed surgical incisions (HTG509)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.
NICE's prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.